Zacks Research Has Bullish Forecast for Neogen Q3 Earnings

Neogen Co. (NASDAQ:NEOG) – Investment analysts at Zacks Research boosted their Q3 2025 earnings per share (EPS) estimates for shares of Neogen in a research report issued on Monday, March 3rd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.12 per share for the quarter, up from their prior forecast of $0.11. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s FY2025 earnings at $0.39 EPS.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Friday, January 10th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.12. The firm had revenue of $231.30 million for the quarter, compared to analyst estimates of $227.16 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same period last year, the company earned $0.11 EPS.

NEOG has been the topic of several other reports. Guggenheim began coverage on Neogen in a research report on Thursday, December 19th. They set a “buy” rating and a $15.00 price target on the stock. Piper Sandler restated a “neutral” rating and set a $13.00 price target (down from $16.50) on shares of Neogen in a research report on Tuesday, January 21st.

Neogen Trading Down 0.6 %

NASDAQ NEOG opened at $9.54 on Thursday. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. Neogen has a twelve month low of $9.01 and a twelve month high of $18.58. The firm has a market capitalization of $2.07 billion, a PE ratio of -4.36 and a beta of 1.27. The stock’s 50 day moving average is $11.24 and its 200 day moving average is $13.62.

Insiders Place Their Bets

In other Neogen news, CEO John Edward Adent purchased 23,035 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was purchased at an average price of $11.03 per share, for a total transaction of $254,076.05. Following the completion of the purchase, the chief executive officer now directly owns 269,164 shares of the company’s stock, valued at $2,968,878.92. This trade represents a 9.36 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO David H. Naemura purchased 14,800 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was acquired at an average price of $11.11 per share, with a total value of $164,428.00. Following the purchase, the chief financial officer now directly owns 61,434 shares of the company’s stock, valued at approximately $682,531.74. The trade was a 31.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.13% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its holdings in Neogen by 142.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,982 shares of the company’s stock valued at $33,000 after acquiring an additional 1,165 shares during the period. Harbour Investments Inc. bought a new position in shares of Neogen in the fourth quarter worth about $27,000. Blue Trust Inc. raised its stake in shares of Neogen by 196.7% in the fourth quarter. Blue Trust Inc. now owns 3,368 shares of the company’s stock worth $41,000 after buying an additional 2,233 shares during the period. Johnson Financial Group Inc. bought a new position in shares of Neogen in the fourth quarter worth about $43,000. Finally, Neo Ivy Capital Management bought a new position in shares of Neogen in the third quarter worth about $66,000. Institutional investors own 96.73% of the company’s stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.